PT-141 Side Effects: What to Expect and What We Screen For

Disclaimer: Compounded PT-141 (bremelanotide) is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This article is for educational purposes only, is not medical advice, and does not establish a provider-patient relationship.

Any honest conversation about a medication includes its side effects, and the PT-141 side effects are worth understanding clearly before you consider it. Most of what patients experience is mild and manageable, but there are a couple of things that genuinely matter and shape who our providers will and will not prescribe it to. Here is the straight version.

The Most Common Side Effect: Nausea

If you take away one thing from this article, make it this: nausea is the most common side effect of PT-141, and it is the most frequent reason people stop using it.

For most who experience it, the nausea is mild to moderate and transient, occurring in the window after dosing. Some patients find it a minor and acceptable tradeoff. Others find it bothersome enough that the medication is not worth it for them. There is no shame in either reaction; it is genuinely individual. What I tell patients is to go in expecting the possibility of nausea rather than being blindsided by it, because expectation changes how manageable it feels.

Dose matters here. Nausea tends to be dose-related, which is one reason a careful provider starts conservatively rather than at a high dose.

Flushing and Injection-Site Reactions

Facial flushing, a warm reddening of the skin, is a commonly reported effect and reflects the medication's activity on melanocortin receptors. It is usually mild and temporary.

Because PT-141 is administered by subcutaneous injection, local injection-site reactions, redness, mild irritation, or temporary discomfort at the site, can also occur. These are typically minor and resolve on their own.

The One That Matters Most: Blood Pressure

This is the side effect that drives the clinical screening, and it is why PT-141 is not appropriate for everyone.

PT-141 can cause a transient increase in blood pressure and a transient decrease in heart rate after dosing.[1] For a healthy person with normal blood pressure, this transient effect is generally not a concern. For someone with uncontrolled hypertension or significant cardiovascular disease, it can be. Melanocortin receptors are present in the cardiovascular system, which is the mechanistic reason for this effect.[2]

This is precisely why our providers evaluate cardiovascular health and blood pressure before prescribing. It is not a formality. Uncontrolled high blood pressure and significant cardiovascular disease are the kinds of findings that lead a provider to decline, and that judgment is the screening working as intended.

A Note on Skin Darkening

Because PT-141 acts on the melanocortin system, which includes the receptors involved in skin pigmentation, some reports note the potential for skin darkening, particularly with repeated or higher-frequency use. PT-141 was specifically designed to reduce activity at the pigmentation receptor relative to its parent compound,[3] and this effect is more associated with related melanocortin compounds used frequently, but it is worth being aware of and discussing with your provider.

Who Should Not Use PT-141

Pulling the screening together, PT-141 is generally not appropriate for people with uncontrolled hypertension, significant or uncontrolled cardiovascular disease, or a history that makes the transient cardiovascular effects risky. It is also not something to use without a provider's evaluation, precisely because these contraindications require clinical judgment to assess.

A responsible program screens for these things before prescribing. If a provider is willing to hand you PT-141 without asking about your cardiovascular health, that is a reason for concern, not convenience.

The Honest Summary

Most PT-141 side effects, nausea, flushing, injection-site reactions, are mild and manageable, with nausea being the most common and the most frequent reason people discontinue. The side effect that actually shapes the clinical decision is the transient effect on blood pressure, which is why cardiovascular screening is central to appropriate prescribing. Understood and screened for properly, the profile is manageable for the right candidate; it is not the right medication for everyone, and knowing which one you are is what the provider evaluation determines.

If you are considering PT-141, that evaluation is a conversation for a licensed provider who can review your health history. See our PT-141 therapy program to learn how our providers evaluate candidates.

References

1. Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PubMed: 12851303

2. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PubMed: 31599840

3. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects. Int J Impot Res. 2004. PubMed: 15833522

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult a licensed provider.